#Israel #Google Cloud #Rehovot #Evogene #ChemPass AI

Evogene and Google Cloud's Expanding Collaboration

Evogene Ltd., a leader in computational chemistry and focused on AI-driven drug design, recently announced a significant expansion of its partnership with Google Cloud aimed at revolutionizing the small-molecule discovery process. Announced on February 10, 2026, this collaboration marks the second phase of their partnership which began in October 2024. The integration of advanced AI Agents into Evogene’s ChemPass AI™ platform is designed specifically for small-molecule discovery and optimization, which is crucial in the pharmaceutical and agricultural industries.

The Importance of AI in Drug Development

The pharmaceutical industry faces stringent demands for speed and efficiency in drug development. As a result, the need to rapidly discover and optimize small molecules has never been more critical. Evogene’s ChemPass AI™ platform addresses this need by enabling scientists to predict, design, and optimize potential drug candidates using artificial intelligence. The new phase of collaboration will harness Google Cloud's Vertex AI platform to further enhance these capabilities.

Key Features of the Expanded Collaboration

1. Integration of Advanced AI Agents: The new AI agents are designed to operate independently, planning and executing complex scientific workflows that accelerate the discovery process. These agents will automate essential discovery processes, enabling researchers to explore multiple molecular candidates simultaneously, thereby enhancing the overall efficiency of the drug development pipeline.

2. Increased Speed and Accuracy: By using AI to handle large-scale molecular exploration, Evogene aims to significantly reduce the design-make-test-analyze cycle time. This improvement is anticipated to lead to higher success rates in identifying small molecules that are commercially viable candidates for pharmaceuticals and agricultural products.

3. Broader Applications and Partnerships: The enhanced capabilities of ChemPass AI™ not only aim to improve the internal workings of Evogene; they are also expected to broaden the company's appeal in partnerships within the biotech sector, fostering collaborations with other entities focused on next-generation molecular design.

Statements from Leadership

Boaz Maoz, Managing Director at Google Cloud Israel, remarked, "This expanded collaboration denotes the immense potential of integrating advanced AI into scientific inquiry. Automating the complexity of discovery workflows will empower Evogene to fast-track its innovative processes."

Ofer Haviv, the CEO of Evogene, expressed enthusiasm regarding the partnership, indicating that the improved speed and efficiency would allow for parallel progression in multiple discovery programs. He also highlighted the potential of making significant aspects of their innovation tools accessible through the Google Cloud Marketplace.

Conclusion

The enhanced collaboration between Evogene and Google Cloud signifies a pivotal move towards automated scientific discovery, with the potential to reshape drug and agricultural product development. Evogene’s commitment to utilizing cutting-edge technologies in its ChemPass AI™ platform not only exemplifies its leadership in computational chemistry but also underscores its vision of achieving real-world innovations to meet pressing industry needs. As Evogene continues to foster partnerships and leverage AI advancements, the future of small-molecule design looks promising and poised for remarkable achievements in healthcare and agriculture.